Kenox Pharmaceuticals, Inc.
Princeton Corporate Plaza 11 Deerpark Drive, Suite 128
Monmouth Junction, NJ 08852
T: (774) 282-4369
E: bd@kenoxpharma.us
W: https://www.kenoxpharma.us/
LinkedIn: https://www.linkedin.com/company/kenox-pharmaceuticals-inc/?

Delivering the Future of Aerosol-Based Therapies

COMPANY DESCRIPTION

Kenox Pharmaceuticals is a specialty contract development, manufacturing, and testing organization advancing nasal, inhalation, and ophthalmic drug products. We provide end-to-end support from early-stage research and formulation development through GMP fill-finish and analytical testing, enabling successful Phase I and II clinical trials.

Our expertise includes both non-sterile and sterile drug–device combination products, ensuring quality and reliability across diverse development programs. Kenox is distinguished by deep technical knowledge, broad industry experience, and flexibility in managing complex device technologies, from conventional inhalers to advanced platforms such as Soft Mist inhalers.

By combining scientific rigor with operational excellence, Kenox helps partners accelerate development timelines, reduce risk, and advance innovative drug delivery solutions across North America and expanding global markets.

SERVICES & CAPABILITIES

Kenox Pharmaceuticals delivers reliable, agile, and cost‑efficient CDMO services for inhalation, intranasal, and ocular therapies. With integrated R&D and GMP facilities, deep expertise in small‑ and large‑molecule development, and a collaborative approach, Kenox supports partners from early research through clinical readiness.

We provide a smooth path to development milestones through a full suite of capabilities, including analytical and formulation development, OINDP testing, GMP manufacturing, and finished product release. Our team manages programs from pre‑clinical stages through Phase I/II, with expanded support for late‑stage development in our new GMP facility.

Development

• Analytical, formulation, and process development
• Small‑scale feasibility batches
• OINDP testing
• Pre‑IND package preparation

QC & IVBE Testing

• Finished product GMP testing and release (Phase I–III and commercial)

Manufacturing

• Batch sizes from hundreds to several thousand units for phase I and II Studies
• Non‑sterile and sterile manufacturing
• Secondary packaging and labeling
• Three clean rooms (wet and dry powder)
• DEA Class II–V material handling

TECHNOLOGIES

Kenox Pharmaceuticals employs advanced technologies purpose‑built for nasal, inhalation, and ophthalmic drug‑device combination products. Our teams develop complex formulations that optimize spray performance, particle size distribution, and device compatibility across diverse delivery platforms.

With precision low‑volume filling, device performance testing, and comprehensive stability capabilities, our technology platforms overcome the unique challenges of OINDP development. These integrated tools enable consistent, patient‑centric delivery and support both small molecules and biologics with accuracy, reliability, and confidence.

FACILITIES

Kenox Pharmaceuticals operates a modern, integrated development and GMP manufacturing facility in Princeton, New Jersey. Purpose‑built for OINDP programs, our site brings formulation, fill‑finish, device handling, and analytical testing together under one roof to ensure seamless progression from concept to clinical supply.